The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses the CaDAnCe-101 trial (NCT05006716), a Phase I study evaluating the safety and efficacy of tacabrutideg, a novel BTK degrader, in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and small lymphocytic lymphoma (SLL). Prof. Stilgenbauer notes promising results, with a high response rate and durable responses, and suggests that tacabrutideg could play a role in earlier lines of treatment, potentially in combination with other novel agents. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
